Literature DB >> 24525599

Pharmacologic targets and peritoneal membrane remodeling.

Karima Farhat1, Andrea W D Stavenuiter, Rob H J Beelen, Piet M Ter Wee.   

Abstract

Peritoneal dialysis (PD) is associated with functional and structural changes of the peritoneal membrane, also known as peritoneal remodeling. The peritoneal membrane is affected by many endogenous and exogenous factors such as cytokines, PD fluids, and therapeutic interventions. Here, we present an overview of various studies that have investigated pharmacologic interventions aimed at regression of peritoneal damage and prolongation of PD treatment.

Keywords:  Therapeutic interventions

Mesh：

Year:  2014        PMID： 24525599      PMCID： PMC3923701          DOI： 10.3747/pdi.2011.00332

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN： 0896-8608            Impact factor:   1.756


  91 in total

1.  Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure.

Authors:  K Honda; K Nitta; S Horita; W Yumura; H Nihei
Journal:  Nephron       Date:  1996       Impact factor: 2.847

Review 2.  Experimental models in peritoneal dialysis: a European experience.

Authors:  N Lameire; W Van Biesen; M Van Landschoot; T Wang; O Heimbürger; J Bergström; B Lindholm; L P Hekking; C E Havenith; R H Beelen
Journal:  Kidney Int       Date:  1998-12       Impact factor: 10.612

3.  Metabolic and vascular factors in the pathogenesis of diabetic neuropathy.

Authors:  N E Cameron; M A Cotter
Journal:  Diabetes       Date:  1997-09       Impact factor: 9.461

4.  In vitro formation of advanced glycation end products in peritoneal dialysis fluid.

Authors:  E J Lamb; W R Cattell; A B Dawnay
Journal:  Kidney Int       Date:  1995-06       Impact factor: 10.612

5.  Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study.

Authors:  M Jones; T Hagen; C A Boyle; E Vonesh; R Hamburger; C Charytan; S Sandroni; D Bernard; B Piraino; M Schreiber; T Gehr; P Fein; M Friedlander; J Burkart; D Ross; S Zimmerman; R Swartz; T Knight; A Kraus; L McDonald; M Hartnett; M Weaver; L Martis; J Moran
Journal:  Am J Kidney Dis       Date:  1998-11       Impact factor: 8.860

6.  Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells.

Authors:  S Kagami; W A Border; D E Miller; N A Noble
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

Review 7.  Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy.

Authors:  Stephen Gately; William W Li
Journal:  Semin Oncol       Date:  2004-04       Impact factor: 4.929

Review 8.  Interleukin/cytokine profiles in haemodialysis and in continuous peritoneal dialysis.

Authors:  Peter Jacobs; Griet Glorieux; Raymond Vanholder
Journal:  Nephrol Dial Transplant       Date:  2004-08       Impact factor: 5.992

9.  Effects of intraperitoneal cyclooxygenase inhibition on inflammatory mediators in dialysate and peritoneal membrane characteristics during peritonitis in continuous ambulatory peritoneal dialysis.

Authors:  D Zemel; D G Struijk; C Dinkla; L M Stolk; I J ten Berge; R T Krediet
Journal:  J Lab Clin Med       Date:  1995-08

Review 10.  Angiotensin II as a renal growth factor.

Authors:  G Wolf; E G Neilson
Journal:  J Am Soc Nephrol       Date:  1993-03       Impact factor: 10.121
View more
  3 in total

1.  Inhibition of EGF Receptor Blocks the Development and Progression of Peritoneal Fibrosis.

Authors:  Li Wang; Na Liu; Chongxiang Xiong; Liuqing Xu; Yingfeng Shi; Andong Qiu; Xiujuan Zang; Haiping Mao; Shougang Zhuang
Journal:  J Am Soc Nephrol       Date:  2015-12-17       Impact factor: 10.121

Review 2.  Is there such a thing as biocompatible peritoneal dialysis fluid?

Authors:  Claus Peter Schmitt; Christoph Aufricht
Journal:  Pediatr Nephrol       Date:  2016-10-08       Impact factor: 3.714

3.  STAT3/HIF-1α signaling activation mediates peritoneal fibrosis induced by high glucose.

Authors:  Xiaoxiao Yang; Manchen Bao; Yi Fang; Xiaofang Yu; Jun Ji; Xiaoqiang Ding
Journal:  J Transl Med       Date:  2021-06-30       Impact factor: 5.531
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.